Comparing 2nd Line Treatment Options for Follicular Lymphoma
As chemo-free strategies continue to reshape follicular lymphoma care, the relapsed setting has become increasingly defined by choice rather than default. “Second-line treatment for follicular lymphoma has been markedly altered by the approval of bispecific antibodies,” says Dr. Catherine Diefenbach of NYU Langone, noting that clinicians are now weighing multiple highly active options with different implications for sequencing and long-term strategy.
- 2nd Line Treatment: Bispecific antibodies have moved earlier in relapsed follicular lymhoma, raising expectations for depth and durability of response compared with historical R²-based approaches.
-
Treatment Decision Factors: Tumor burden, POD24 status, prior therapy, patient fitness, and tolerance for monitoring increasingly guide selection among bispecifics, Monjuvi-based regimens, and CAR T.
-
Sequencing Options: With multiple active options available, preserving later-line therapies—particularly CAR T—has become a strategic decision rather than a necessity.
More Options, More Judgment: Making Sense of Second-Line Follicular Lymphoma
Frontline treatment for follicular lymphoma (FL) has evolved steadily toward chemo-free, immune-based approaches. As those strategies improve disease control up front, second-line FL is no longer defined by a default pathway, but by choice. Multiple effective regimens are now available, each with different tradeoffs around depth of response, durability, toxicity, and sequencing.
“Second-line treatment for follicular lympomha has been markedly altered by the approval of bispecific antibodies,” says Dr. Catherine Diefenbach of NYU. “We now have several highly active options, which means clinicians have to be more deliberate about how they choose and sequence therapy.”
That shift has moved the conversation away from whether an option works and toward how, when, and for whom it should be used.
Decision Points Still Start With Biology
Despite the expanding menu of therapies, the initial decision of whether to treat at relapse remains grounded in fundamentals. Tumor burden and symptoms—often guided by GELF criteria—still determine when therapy is required. Beyond that, Dr. Diefenbach emphasizes that the most important prognostic determinant is duration of response, particularly early relapse.
“The decision of whether and when to treat is generally contingent on tumor burden and symptoms,” she says. “But the most important prognostic factor is how long the prior response lasted—especially relapse within 24 months.”
Patients with POD24 represent a distinct population in whom deeper, more durable disease control is often prioritized earlier in the relapse setting.
EPCO-R2 Raises the Bar in Second Line
Among the most practice-shaping developments is the emergence of epcoritamab combined with rituximab and lenalidomide (EPCO-R2). In a randomized phase III study, the addition of epcoritamab to R² produced markedly higher response rates and a substantial reduction in the risk of disease progression compared with R² alone, including in patients with higher-risk features.
“These data support EPCO-R2 as a clear standard of care for fit patients in the second line who have not previously received rituximab and lenalidomide,” Dr. Difeenbach says.
Equally important for real-world adoption, the safety profile has been consistent with expectations for bispecific antibodies, with predominantly low-grade cytokine release syndrome and manageable cytopenias. The ability to deliver therapy largely in the outpatient setting has made this approach feasible for many patients who might otherwise have required more intensive regimens.
Bispecifics Are Not One-Size-Fits-All
While EPCO-R2 has raised expectations for second-line efficacy, it is not the only bispecific option influencing practice. Mosunetuzumab offers a differentiated profile, including fixed-duration therapy and a favorable tolerability spectrum.
“The data for Lunsumio suggest a regimen that is limited in duration, very well tolerated, and capable of producing long responses,” Dr. Diefenbach notes.
Rather than competing head-to-head, these regimens often occupy different positions in sequencing, depending on patient priorities, prior therapies, and tolerance for prolonged treatment. Fixed-duration approaches may be particularly attractive for patients seeking disease control without committing to extended therapy or frequent clinic visits.
Where Monjuvi Fits in a Crowded Field
The expansion of bispecific antibodies has also reshaped the role of tafasitamab-based regimens. Tafasitamab combined with R² remains a chemo-free option with a differentiated safety profile, notably avoiding direct T-cell engagement.
In practice, this approach may be favored for patients who are less suitable candidates for bispecific therapy due to concerns around cytokine release syndrome, monitoring requirements, or immune-mediated toxicity. However, compared with newer bispecific regimens, tafasitamab-based approaches typically involve more frequent visits and lower overall activity, which increasingly influences positioning as more potent options move earlier.
CAR T Moves Later for Many Patients
CAR T-cell therapy continues to offer deep and durable remissions for selected patients, but its role is evolving in the context of effective off-the-shelf alternatives.
“CAR T has significantly more upfront toxicity, as well as long-term risks, including prolonged cytopenias,” Dr. Diefenbach says. “I generally reserve it for patients who relapse after bispecific antibody therapy.”
The availability of highly active bispecifics has allowed many clinicians to delay referral for cellular therapy, preserving CAR T as a later-line option rather than an early escalation strategy—particularly for patients who achieve meaningful disease control with antibody-based regimens.
Looking Ahead: More Options, Better Sequencing
As additional data mature, second-line FL is likely to become even more nuanced. Emerging strategies include next-generation cereblon modulators and rational combinations pairing bispecific antibodies with targeted oral agents, aiming to deepen responses without sacrificing tolerability.
Rather than narrowing choices, these developments reinforce the need for individualized sequencing, informed by disease biology, prior treatment exposure, patient fitness, and long-term goals.
“All of these represent active options for relapsed follicular lymphoma patients,” Dr. Diefenbach says. “It’s a wonderful challenge to have so many effective therapies—but it makes thoughtful decision-making more important than ever.”
